RJA
HZNP

Raymond James & Associates’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Raymond James & Associates’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-127,300
Closed -$203K – 3761
2018
Q4 		$203K Sell
127,300
-3,600
-3% -$70.6K ﹤0.01% 3124
2018
Q3 		$268K Buy
+130,900
New +$2.49M ﹤0.01% 3110
2017
Q1 		– Sell
-10,400
Closed -$1K – 3447
2016
Q4 		$1K Buy
+10,400
New +$189K ﹤0.01% 3234
2015
Q4 		– Sell
-155,400
Closed -$365K – 2432
2015
Q3 		$365K Sell
155,400
-4,200
-3% -$133K ﹤0.01% 2063
2015
Q2 		$1.87M Hold
159,600
– – 0.01% 1359
2015
Q1 		$1M Buy
+159,600
New +$2.93M ﹤0.01% 1655

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Raymond James & Associates's HZNP Position: Q4 2023 in Review

Raymond James & Associates sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 7,342 shares — an estimated $849K sold.

Raymond James & Associates first reported a position in HZNP in Q4 2014 and held it in 36 quarters. The position peaked at $26.8M in Q1 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Raymond James & Associates reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Raymond James & Associates sold 7,342 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $849K.
  • Raymond James & Associates first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2014 and held it in 36 quarters.
  • Raymond James & Associates's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $26.8M in Q1 2022.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Raymond James & Associates's 13F filing for Q4 2023, filed 16 Jan 2024.